STOCK TITAN
  1. Home
  2. Sec-filings
  3. LKFT
  4. [6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer)

Lakefront Biotherapeutics (LKFT) repurchases 98,648 shares in July

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics reports that, under its share repurchase program announced on June 9, 2026, it bought back 98,648 ordinary shares between July 13 and July 17, 2026 through an independent financial intermediary. The shares were acquired on several European trading venues at an average price of €26.00, for a total consideration of €2,564,633.73 and within a price range of €25.60 to €26.56.

Following these transactions, Lakefront holds 511,049 of its own ordinary shares. The company describes itself as a biotechnology business focused on immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases, and includes forward-looking statements regarding its ongoing share repurchase plans.

Positive

  • None.

Negative

  • None.
Shares repurchased 98,648 shares Between July 13 and July 17, 2026 under repurchase program
Average repurchase price €26.00 Weighted average price per share over the July 13–17, 2026 period
Total repurchase cost €2,564,633.73 Aggregate consideration for 98,648 shares repurchased July 13–17, 2026
Repurchase price range €25.60–€26.56 Lowest and highest prices paid per share during the period
Own shares held 511,049 shares Treasury shares held as of market close on July 17, 2026
repurchase program financial
"Within the framework of the repurchase program announced on June 9, 2026"
A repurchase program is when a company buys back its own shares from the open market. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's future. For investors, it often suggests that the company believes its stock is undervalued and can be a sign of financial strength.
discretionary mandate financial
"it has repurchased 98,648 Lakefront shares via a discretionary mandate"
independent financial intermediary financial
"via a discretionary mandate to an independent financial intermediary"
BCMAxCD3 T‑cell engager medical
"anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What share repurchases did Lakefront Biotherapeutics (LKFT) complete between July 13 and 17, 2026?
Lakefront Biotherapeutics repurchased 98,648 ordinary shares between July 13 and 17, 2026. The shares were bought under its June 9, 2026 repurchase program, executed through an independent financial intermediary across several European trading venues.

What was the total amount spent and average price in Lakefront Biotherapeutics (LKFT) July 2026 buybacks?
Lakefront spent €2,564,633.73 to repurchase shares at an average price of €26.00 per share. During the July 13–17, 2026 period, transaction prices ranged between €25.60 and €26.56 across the XAMS, CEUX, AQEU, and TQEX markets.

How many own shares does Lakefront Biotherapeutics (LKFT) hold after these repurchases?
As of market close on July 17, 2026, Lakefront holds 511,049 of its own ordinary shares. This treasury position reflects cumulative purchases under its ongoing share repurchase program, including the 98,648 shares bought between July 13 and 17, 2026.

On which markets did Lakefront Biotherapeutics (LKFT) execute its July 2026 share repurchases?
The July 13–17, 2026 repurchases were executed on XAMS, CEUX, AQEU, and TQEX. Transactions took place across these European trading venues under a discretionary mandate given to an independent financial intermediary managing Lakefront’s share buyback orders.

What type of company is Lakefront Biotherapeutics (LKFT) and what is its lead program?
Lakefront Biotherapeutics is a biotechnology company focused on immunology and inflammation. Its portfolio is anchored by gamgertamig, described as a potential first‑in‑class BCMAxCD3 T‑cell engager being developed for autoimmune diseases, alongside other acquired and internally advanced pipeline assets.
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On July 21, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated July 21, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: July 21, 2026     /s/ Ying Deng    
  Ying Deng
  Authorized Officer
  

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; July 21, 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between July 13, 2026 and July 17, 2026 it has repurchased 98,648 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:

Date of purchaseMarket/MTFNumber of sharesAverage price paid (€)Total (€)Lowest price paid (€)Highest price paid (€)
13/07/2026XAMS20,58326.38543,006.3026.1226.56
13/07/2026CEUX1,84226.3948,613.3326.3026.54
13/07/2026AQEU23826.416,286.1326.3426.54
13/07/2026TQEX53226.4114,049.6926.3426.46
14/07/2026XAMS19,82526.01515,672.0425.7426.34
14/07/2026CEUX2,28925.9959,486.0725.8426.20
14/07/2026AQEU17025.864,396.2025.8625.86
14/07/2026TQEX98726.0825,736.8126.0626.18
15/07/2026XAMS15,77025.75406,156.3525.6225.96
15/07/2026CEUX42225.7310,857.4725.6225.78
15/07/2026AQEU47625.7212,244.1525.6225.76
15/07/2026TQEX90625.7923,368.7325.6225.80
16/07/2026XAMS16,48525.93427,428.0325.7626.10
16/07/2026CEUX1,13725.9329,483.8925.8826.00
16/07/2026AQEU6825.921,762.5625.9225.92
16/07/2026TQEX52825.9413,695.2125.9225.94
17/07/2026XAMS14,97225.77385,768.5525.6026.04
17/07/2026CEUX1,36825.8335,337.2225.7026.02
17/07/2026TQEX5025.701,285.0025.7025.70
Total 98,64826.002,564,633.7325.6026.56

As of market close on July 17, 2026, Lakefront holds 511,049 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases